+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


CytoSorbents Corp (CTSO) - Product Pipeline Analysis, 2019 Update

  • ID: 4239744
  • Company Profile
  • August 2019
  • 45 pages
  • GlobalData


  • Aethlon Medical Inc
  • Hologic Inc
  • NxStage Medical Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriously ill patients by reducing excessive cytokines and bacterial toxins. CytoSorbents’ CytoSorb is also being administered during and after cardiac surgery to prevent post-operative complications such as multiple organ failure. The company offers VetResQ, a blood purification adsorber, to support and treat excessive inflammation and toxic injury in animals. The company offers its products through a network of distributors across Europe, the Middle East and Asia Pacific. CytoSorbents is headquartered in Monmouth Junction, New Jersey, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company CytoSorbents Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown


  • Aethlon Medical Inc
  • Hologic Inc
  • NxStage Medical Inc
CytoSorbents Corp Company Overview
  • CytoSorbents Corp Company Snapshot
  • CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview
  • CytoSorbents Corp – Pipeline Analysis Overview
  • CytoSorbents Corp - Key Facts
  • CytoSorbents Corp - Major Products and Services
  • CytoSorbents Corp Pipeline Products by Development Stage
  • CytoSorbents Corp Ongoing Clinical Trials by Trial Status
  • CytoSorbents Corp Pipeline Products Overview
  • BetaSorb
  • BetaSorb Product Overview
  • ContrastSorb
  • ContrastSorb Product Overview
  • CST 301
  • CST 301 Product Overview
  • CytoSorb
  • CytoSorb Product Overview
  • CytoSorb Clinical Trial
  • CytoSorb-XL
  • CytoSorb-XL Product Overview
  • DrugSorb
  • DrugSorb Product Overview
  • HemoDefend
  • HemoDefend Product Overview
  • K+ontrol
  • K+ontrol Product Overview
  • CytoSorbents Corp - Key Competitors
  • CytoSorbents Corp - Key Employees
  • CytoSorbents Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • CytoSorbents Corp, Recent Developments
  • Aug 13, 2019: CytoSorbents expands CytoSorb distribution in Latin America to Brazil, Colombia, and Costa Rica
  • Aug 06, 2019: CytoSorbents reports record second quarter 2019 financial results
  • Aug 05, 2019: CytoSorbents announces amendment to loan agreement with Bridge Bank, receives an additional $5 million cash from new term loan
  • May 07, 2019: CytoSorbents annopunces first quarter 2019 financial results
  • Apr 24, 2019: CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences
  • Mar 25, 2019: Israel approves CytoSorb registration, CytoSorbents announces Gad Medical as distributor
  • Mar 07, 2019: CytoSorbents achieves record revenue and product sales growth in 2018
  • Mar 05, 2019: CytoSorbents expands direct sales to Poland, the Nordics, and the Netherlands
  • Feb 05, 2019: CytoSorbents to present at the 21st Annual BIO CEO & Investor Conference
  • Feb 04, 2019: CytoSorbents announces the Data Safety Monitoring Board recommends continuation of REMOVE Endocarditis Trial
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview
  • CytoSorbents Corp Pipeline Products by Equipment Type
  • CytoSorbents Corp Pipeline Products by Indication
  • CytoSorbents Corp Ongoing Clinical Trials by Trial Status
  • CytoSorbents Corp, Key Facts
  • CytoSorbents Corp, Major Products and Services
  • CytoSorbents Corp Number of Pipeline Products by Development Stage
  • CytoSorbents Corp Pipeline Products Summary by Development Stage
  • CytoSorbents Corp Ongoing Clinical Trials by Trial Status
  • CytoSorbents Corp Ongoing Clinical Trials Summary
  • BetaSorb - Product Status
  • BetaSorb - Product Description
  • ContrastSorb - Product Status
  • ContrastSorb - Product Description
  • CST 301 - Product Status
  • CST 301 - Product Description
  • CytoSorb - Product Status
  • CytoSorb - Product Description
  • CytoSorb - Case-observation and Compassionate Use: Use of Extracorporeal Treatment with the Cytosorb-adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery with the Use of a Heart-lung-machine
  • CytoSorb - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation
  • CytoSorb - Cytokine Adsorption in Sepsis and Acute Kidney Injury
  • CytoSorb - CytoSorb Reduction of Freee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)
  • CytoSorb - Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)
  • CytoSorb - Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients with Sepsis and Acute Kidney Injury
  • CytoSorb - Evaluating a CytoSorb Score in Septic Shock - A Retrospective Multicenter Data Analysis
  • CytoSorb - Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - A Randomized Study : EXCESS
  • CytoSorb - Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients with Rhabdomyolysis
  • CytoSorb - HaemoAdsorption Nach Reanimation an ECMO
  • CytoSorb - Hemoadsorption with CytoSorb in Post-Cardiac Arrest Syndrome: a Pilot Study (The CATCH Trial: Post Cardiac Arrest Therapy with Cytosorb Hemoadsorption)
  • CytoSorb - Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery
  • CytoSorb - International Registry on the Use of the CytoSorb-Adsorber in ICU Patients
  • CytoSorb - Pancreatitis CytoSorbents (CytoSorb) Inflammatory Cytokine Removal: A Prospective Study
  • CytoSorb - Removal of Cytokine on Cardiopulmonary Bypass with CytoSorb Compared to on- and Off-pump Myocardial Revascularization
  • CytoSorb - Removal of Cytokines During Cardiac Surgery
  • CytoSorb - Removal of Cytokines in Patients Undergoing Cardiac Surgery with CPB (The REMOTE Study)
  • CytoSorb - Revealing Mechanisms and Investigating Efficacy of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients with Infective Endocarditis - A Multicentric Randomized Controlled Group Sequential Trial
  • CytoSorb - The Impact of Pre-emptive Intraoperative Use of Extracorporeal Cytokine Adsorption during Orthotopic Heart Transplantation
  • CytoSorb-XL - Product Status
  • CytoSorb-XL - Product Description
  • DrugSorb - Product Status
  • DrugSorb - Product Description
  • HemoDefend - Product Status
  • HemoDefend - Product Description
  • K+ontrol - Product Status
  • K+ontrol - Product Description
  • CytoSorbents Corp, Key Employees
  • CytoSorbents Corp, Subsidiaries
  • Glossary
List of Figures
  • CytoSorbents Corp Pipeline Products by Equipment Type
  • CytoSorbents Corp Pipeline Products by Development Stage
  • CytoSorbents Corp Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown


A selection of companies mentioned in this report includes:

  • Aethlon Medical Inc
  • NxStage Medical Inc
  • Hologic Inc
  • HemoCleanse Technologies LLC
Note: Product cover images may vary from those shown